SingaporeTuberculosis profile
Population  2015 5.6 million
Estimates of TB burden*, 2015 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.07 (0.058–0.083) 1.2 (1–1.5)
Mortality (HIV+TB only) <0.01 (<0.01–0.03) 0.11 (0–0.53)
Incidence  (includes HIV+TB) 2.5 (2.1–2.9) 44 (38–51)
Incidence (HIV+TB only) 0.045 (0.039–0.053) 0.81 (0.69–0.94)
Incidence (MDR/RR-TB)** 0.034 (0.018–0.05) 0.61 (0.32–0.89)
Estimated TB incidence by age and sex (thousands)*, 2015
  0-14 years > 14 years Total
Females 0.12 (0.092–0.15) 0.87 (0.62–1.1) 1 (0.71–1.3)
Males 0.062 (0.043–0.08) 1.4 (1.1–1.7) 1.5 (1.2–1.8)
Total 0.18 (0.14–0.23) 2.3 (2.1–2.5) 2.5 (2.1–2.9)
TB case notifications, 2015  
Total cases notified 2 171
Total new and relapse 2 166
          - % tested with rapid diagnostics at time of diagnosis 50%
          - % with known HIV status 87%
          - % pulmonary 85%
          - % bacteriologically confirmed among pulmonary 64%
Universal health coverage and social protection  
TB treatment coverage (notified/estimated incidence), 2015 87% (75–100)
TB patients facing catastrophic total costs  
TB case fatality ratio (estimated mortality/estimated incidence), 2015 0.03 (0.02–0.04)
TB/HIV care in new and relapse TB patients, 2015 Number (%)
Patients with known HIV-status who are HIV-positive 34 2%
          - on antiretroviral therapy    
Drug-resistant TB care, 2015 New cases Previously treated
cases
Total
number***
Estimated MDR/RR-TB cases among notified
pulmonary TB cases
  19
(8–30)
Estimated % of TB cases with MDR/RR-TB 1% (0.52–1.8) 0.99% (0.03–5.4)  
% notified tested for rifampicin resistance 65% 64% 1 400
MDR/RR-TB cases tested for resistance to second-line drugs   13
Laboratory-confirmed cases MDR/RR-TB: 13, XDR-TB: 0
Patients started on treatment **** MDR/RR-TB: 12, XDR-TB: 0
Treatment success rate and cohort size Success Cohort
New and relapse cases registered in 2014 78% 2 143
Previously treated cases, excluding relapse, registered in 2014   0
HIV-positive TB cases, all types, registered in 2014 82% 50
MDR/RR-TB cases started on second-line treatment in 2013 27% 15
XDR-TB cases started on second-line treatment in 2013   0
TB preventive treatment, 2015  
% of HIV-positive people (newly enrolled in care) on preventive treatment <1%
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment
100% (100–100)
TB financing, 2016  
National TB budget (US$ millions) 11
* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history
**** Includes patients diagnosed before 2015 and patients who were not laboratory-confirmed
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population per year)
Incidence graph
   Incidence
   Notified (new and relapse)
   Incidence (HIV+TB only)

Notified cases by age group and sex, 2015
age_sex_graph
____
FemalesMales

Treatment success rate (%)
tx success graph
   
New and relapse
   Retreatment, excluding relapse
   HIV-positive   MDR/RR-TB   XDR-TB

 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2016-12-09 Data: www.who.int/tb/data